Movement Trials

In this first positive phase 3 trial in ataxia-telangiectasia, levacetylleucine produced a statistically significant and clinically meaningful improvement in SARA (treatment effect −1·88 points, 95...

In 90 patients with Hoehn & Yahr stage 1-1.5 Parkinson's disease, a single dose of LCE and LB produced similar plasma dopamine elevations at 90 and 180 minutes, with no significant between-group or in...

Does staged, bilateral MRgFUS pallidothalamic tractotomy offer a favorable risk-benefit profile for advanced Parkinson's disease with motor complications?

Can fixed-dose tavapadon, a selective D1/D5 agonist, improve motor function in early Parkinson disease while avoiding the adverse effects of D2/D3 agonists?

Does continuous subcutaneous infusion of levodopa or foslevodopa reduce daily OFF-time more effectively than oral levodopa in Parkinson's disease patients with motor fluctuations?

Does azathioprine, a broadly acting peripheral immunosuppressant, slow clinical progression in early Parkinson's disease as measured by the MDS-UPDRS gait-axial score?

Intrathecal BIIB094 was generally well tolerated with no drug-related serious adverse events and produced robust, dose-related lowering of CSF LRRK2 protein (up to 59%) and phosphorylated Rab10 (up to...

Bilateral GPi tbTUS produced a clinically meaningful 4.1-point reduction in MDS-UPDRS-III at 30 min post-sonication (p=0.002), driven primarily by bradykinesia improvement; M1-only and dual-site M1+GP...

Home-based bilateral taVNS reduced MDS-UPDRS-III by 6.10 points and significantly improved quality of life, sleep, and autonomic function vs sham over 3 weeks, with elevated serum acetylcholine and re...

Bilateral M1-iTBS produced a 30.7% reduction in MDS-UPDRS Part III at 2 weeks (vs 14.3% sham, p=0.036) plus large improvements in depression (-47.6%) and anxiety (-37.9%), accompanied by increased cer...

Does the anti-α-synuclein monoclonal antibody amlenetug slow clinical disease progression in patients with multiple system atrophy?

Does ecopipam, a selective dopamine D1 receptor antagonist, maintain tic improvement and remain well tolerated for up to 24 weeks in patients with Tourette syndrome?

Can once-daily tavapadon, a selective D1/D5 dopamine agonist, improve motor control and reduce off-time in Parkinson disease patients with motor fluctuations on levodopa while minimizing adverse events?